In this article4
Starting January 1, 2027, the negotiated price for a 30-day supply of Ozempic, Rybelsus and Wegovy is $274, compared with a 2024 list price of $959, along with lower prices for 14 other drugs. If you take one of these drugs, here's what the new prices mean for what you pay, how Medicare covers Wegovy for weight loss, and what to check before Open Enrollment ends December 7.
📋Quick Summary
- Medicare's negotiated price for Ozempic, Rybelsus and Wegovy is $274 for a 30-day supply starting January 1, 2027, compared with a 2024 list price of $959.
- Fourteen other drugs also get negotiated prices in 2027, including Trelegy Ellipta, Xtandi, Ibrance and Linzess.
- The negotiated price isn't your copay. What you pay depends on your plan's cost sharing.
- Separately, a temporary Medicare program lets people who qualify get Wegovy, Foundayo or the Zepbound KwikPen for weight loss for a $50 monthly copayment through December 31, 2027.
- Open Enrollment runs through December 7. Check that your drugs are on your plan's 2027 drug list.
Which Drugs Get Lower Medicare Prices in 2027
CMS negotiated prices for 15 drugs covered under Medicare Part D that take effect January 1, 2027. When the prices go into effect, CMS estimates that people with Medicare drug coverage would save about $685 million in out-of-pocket costs under the standard benefit design.
Medicare negotiated prices for 2027 (30-day supply)
| Drug | Negotiated price | 2024 list price |
|---|---|---|
| Ozempic, Rybelsus, Wegovy | $274 | $959 |
| Trelegy Ellipta | $175 | $654 |
| Xtandi | $7,004 | $13,480 |
| Pomalyst | $8,650 | $21,744 |
| Ofev | $6,350 | $12,622 |
| Ibrance | $7,871 | $15,741 |
| Linzess | $136 | $539 |
| Calquence | $8,600 | $14,228 |
| Austedo, Austedo XR | $4,093 | $6,623 |
| Breo Ellipta | $67 | $397 |
| Xifaxan | $1,000 | $2,696 |
| Vraylar | $770 | $1,376 |
| Tradjenta | $78 | $488 |
| Janumet, Janumet XR | $80 | $526 |
| Otezla | $1,650 | $4,722 |
Source: CMS. List prices are 2024 wholesale acquisition costs for a 30-day supply.
The negotiated price isn't your copay. Your Part D plan sets your deductible, copays and coinsurance, so check your own plan's 2027 costs. CMS estimates people with Part D coverage would save about $685 million in out-of-pocket costs under the standard benefit design.
What It Means for Ozempic, Wegovy and Rybelsus
Ozempic, Rybelsus and Wegovy share one negotiated price of $274 for a 30-day supply.
If you take a GLP-1 drug like Ozempic for type 2 diabetes, you get it through your Part D plan. Your cost in 2027 depends on that plan. In 2027, the standard Part D deductible rises to $700, and the out-of-pocket cap rises to $2,400, after which you pay nothing more for covered drugs that year. Our Part D guide explains how the 2027 cap works.
Related Medicare Updates
What About Wegovy for Weight Loss?
The negotiated price is separate from Medicare's temporary GLP-1 Bridge, which covers Wegovy, Foundayo and the KwikPen version of Zepbound for weight loss for a $50 monthly copayment through December 31, 2027. It has its own eligibility rules, including body mass index requirements, and people with type 2 diabetes aren't eligible for it because their Part D plan may cover their GLP-1 instead. Our guide to the GLP-1 Bridge explains who qualifies and how to get started.
What to Check Before December 7
- Make sure each of your drugs is on your plan's 2027 drug list, called a formulary, and note its 2027 cost. Your plan's Annual Notice of Change lists what's changing.
- Compare plans on Medicare's Plan Finder using your exact drugs and doses.
- If your income is limited, ask about Extra Help, which can lower Part D costs.
- Make any change by December 7 so it starts January 1.
- Shop safely. Type Medicare.gov yourself instead of clicking search ads.
✅What This Means For You
If you take Ozempic or Rybelsus for diabetes: Your Part D plan still covers it. Use Plan Finder to compare what it will cost you in 2027 under your plan and others.
If you want Wegovy or Zepbound for weight loss: That's covered separately through the GLP-1 Bridge for $50 a month if you qualify. Our Bridge guide explains the rules.
If you take another drug on the list: Lower Medicare prices can mean lower costs, but your plan's design decides your copay. Compare your 2027 costs before December 7.
If money is tight: Extra Help can lower your Part D costs, though it doesn't apply to the $50 Bridge copay.
Explore Further
Common questions about Ozempic, Wegovy and Medicare in 2027
- Will Ozempic cost less on Medicare in 2027?
- Starting January 1, 2027, the negotiated price for a 30-day supply of Ozempic, Rybelsus and Wegovy is $274, compared with a 2024 list price of $959. What you pay depends on your drug plan's cost sharing.
- Does Medicare cover Wegovy for weight loss?
- Through the temporary Medicare GLP-1 Bridge, people who qualify can get Wegovy, Foundayo or Zepbound KwikPen for weight loss for a $50 monthly copayment through December 31, 2027. There are body mass index and health requirements, and your doctor may need to complete a prior authorization.
- Which drugs get Medicare negotiated prices in 2027?
- Ozempic, Rybelsus and Wegovy, plus Trelegy Ellipta, Xtandi, Pomalyst, Ofev, Ibrance, Linzess, Calquence, Austedo, Breo Ellipta, Xifaxan, Vraylar, Tradjenta, Janumet and Otezla.
- Does the $50 GLP-1 copay count toward the Part D out-of-pocket cap?
- No. CMS says the GLP-1 Bridge copay doesn't count toward your Part D out-of-pocket costs, and the Part D deductible doesn't apply.
- What should I do during Open Enrollment if I take one of these drugs?
- Check that your drug is on your plan's 2027 drug list and compare plans on Medicare Plan Finder using your exact prescriptions before December 7.
